Celgene Corp (CELG) 148.14 $CELG
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
Final Glance: Biotechnology companies
AP - Wed May 21, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed May 21, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Celgene Inks Licensing Deal with AADi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 10:30AM CDT
Celgene (CELG) has out licensed ABI-009 to AADi.
Early Glance: Biotechnology companies
AP - Wed May 21, 9:22AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth
PR Newswire - Wed May 21, 7:41AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Celgene Corporation (NASDAQ: CELG), Novartis AG (NYSE: NVS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2747-100free.
AADi signs licensing agreement with Celgene for nanotechnology-based drug candidate ABI-009
M2 - Wed May 21, 4:02AM CDT
Biopharmaceutical company AADi stated on Tuesday that it has entered into an agreement to license the nanotechnology drug candidate ABI-009 from Celgene (NasdaqGS:CELG).
Biotech Tweet of the Week: Share Buybacks
Brian Orelli, The Motley Fool - Motley Fool - Tue May 20, 5:30PM CDT
We've got a pair of related tweets on this week's episode of Biotech Banter . The first is from Jason Napodano, an analyst at Zacks, who asks, "Does anyone actually finish a share buyback in biotech, or do they just announced another one after they...
FDA Designation for Bristol-Myers/AbbVie Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 20, 10:40AM CDT
Bristol-Myers (BMY) and AbbVie (ABBV) announced that the FDA has granted breakthrough therapy designation to elotuzumab.
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
PR Newswire - Tue May 20, 8:00AM CDT
AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the nab® platform that is behind the success of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).
Celgene Corporation to Present at Investor Conferences in June
Business Wire - Tue May 20, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at three upcoming investor conferences in the month of June. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
GlobeNewswire - Mon May 19, 7:05AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ), and CRD Analytics today announced the results of the semi-annual re-ranking of the NASDAQ OMX CRD Global Sustainability Index (Nasdaq:QCRD), which will become effective prior to market open on Monday, May 19, 2014.
3 Companies Frightened by This Medicare Study
Todd Campbell, The Motley Fool - Motley Fool - Sun May 18, 6:05AM CDT
Everyone knows that medical costs are soaring, and that those costs present one of the biggest financial challenges to the next generation. But far fewer know that one of the biggest drug buyers, the Centers for Medicare and Medicaid Services, or...
After Yesterday's Decline of 1.03%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Fri May 16, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Celgene to Potentially Rebound After Falling 1.03% Yesterday
Comtex SmarTrend(R) - Fri May 16, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
Final Glance: Biotechnology companies
AP - Wed May 21, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed May 21, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Celgene Inks Licensing Deal with AADi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 10:30AM CDT
Celgene (CELG) has out licensed ABI-009 to AADi.
Early Glance: Biotechnology companies
AP - Wed May 21, 9:22AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth
PR Newswire - Wed May 21, 7:41AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Celgene Corporation (NASDAQ: CELG), Novartis AG (NYSE: NVS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2747-100free.
AADi signs licensing agreement with Celgene for nanotechnology-based drug candidate ABI-009
M2 - Wed May 21, 4:02AM CDT
Biopharmaceutical company AADi stated on Tuesday that it has entered into an agreement to license the nanotechnology drug candidate ABI-009 from Celgene (NasdaqGS:CELG).
Biotech Tweet of the Week: Share Buybacks
Brian Orelli, The Motley Fool - Motley Fool - Tue May 20, 5:30PM CDT
We've got a pair of related tweets on this week's episode of Biotech Banter . The first is from Jason Napodano, an analyst at Zacks, who asks, "Does anyone actually finish a share buyback in biotech, or do they just announced another one after they...
FDA Designation for Bristol-Myers/AbbVie Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 20, 10:40AM CDT
Bristol-Myers (BMY) and AbbVie (ABBV) announced that the FDA has granted breakthrough therapy designation to elotuzumab.
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
PR Newswire - Tue May 20, 8:00AM CDT
AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the nab® platform that is behind the success of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).
Celgene Corporation to Present at Investor Conferences in June
Business Wire - Tue May 20, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at three upcoming investor conferences in the month of June. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
GlobeNewswire - Mon May 19, 7:05AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ), and CRD Analytics today announced the results of the semi-annual re-ranking of the NASDAQ OMX CRD Global Sustainability Index (Nasdaq:QCRD), which will become effective prior to market open on Monday, May 19, 2014.
3 Companies Frightened by This Medicare Study
Todd Campbell, The Motley Fool - Motley Fool - Sun May 18, 6:05AM CDT
Everyone knows that medical costs are soaring, and that those costs present one of the biggest financial challenges to the next generation. But far fewer know that one of the biggest drug buyers, the Centers for Medicare and Medicaid Services, or...
After Yesterday's Decline of 1.03%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Fri May 16, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Celgene to Potentially Rebound After Falling 1.03% Yesterday
Comtex SmarTrend(R) - Fri May 16, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
